Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Jimmy MaRobin M NanceJoseph A C DelaneyBridget M WhitneyLaura BamfordRonnie M GravettRichard D MooreSonia NapravnikKenneth H MayerJeffrey M JacobsonKaterina ChristopoulosGreer A BurkholderJeanne KerulyJoseph J EronJeffrey MartinEdward R CachayMichael S SaagHeidi M CraneMari M KitahataPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.